When your patient is enrolled in ACTEMRA Access Solutions, a qualified Case Manager will work with both of you throughout your journey with ACTEMRA.
Case Managers are not healthcare professionals and cannot provide medical advice.
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Brunner H, Ruperto N, Zuber A, et al. Arthritis & Rheumatism. 2012;64(10S):S682.
Brunner H, Ruperto N, Zuber A, et al. Arthritis & Rheumatism. 2012;64(10S):S682.
Brunner HI, et al. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Presented at the 2017 Pediatric Rheumatology Symposium in Houston, TX; May 17-20, 2017. PRSYM Oral Presentation.
Brunner HI, et al. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Presented at the 2017 Pediatric Rheumatology Symposium in Houston, TX; May 17-20, 2017. PRSYM Oral Presentation.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.